Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Study of Medtronic Endeavor® Drug-Eluting Stent Demonstrates Long-Term Advantages over Taxus® DES

November 9, 2011 By AxoGen, Inc.

SAN FRANCISCO–(BUSINESS
WIRE
)–New research findings released at TCT 2011 show that the Endeavor®
zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed
Boston Scientific Corp.s Taxus® paclitaxel-eluting stent on standard measures
of safety and efficacy through five years of clinical follow-up.

The findings come from ENDEAVOR IV, a randomized trial
involving nearly 1,550 patients with coronary artery disease that compared the
two drug-eluting stents head-to-head.

A separate analysis released at the same meeting of
interventional cardiovascular specialists also affirmed the strong, long-term
safety profile of Medtronics Endeavor DES, which elutes the drug zotarolimus
from a highly biocompatible polymer that mimics the surface of a red blood
cell.

The final five-year results of ENDEAVOR IV, presented today
by co-principal investigator Dr. David Kandzari of Piedmont Heart Institute in
Atlanta during the Cardiovascular Research Foundations annual Transcatheter
Cardiovascular Therapeutics (TCT) scientific symposium, show statistically
significant differences favoring the Endeavor DES on cardiac death/myocardial
infarction (CD/MI) and very late stent thrombosis (VLST). The data also show a
trend toward lower rates of target vessel failure (TVF) with the Endeavor DES
in long-term follow-up.

“The five-year results from ENDEAVOR IV confirm that
long-term clinical outcomes should be an essential consideration when making
decisions related to stent selection,” said Dr. Kandzari. “Interventionalists
treating patients with coronary artery disease now have ample data to
distinguish the important differences between the performance of these two
drug-eluting stents.”

5-YEAR RESULTS

ENDEAVOR IV

N=1,548

Endeavor vs. Taxus

Endpoint*

 

Endeavor

n=773

 

Taxus

n=775

 

p Value

TVF

 

17.2%

 

21.1%

 

p=0.061

TLR

 

7.7%

 

8.6%

 

p=0.70

CD/MI

 

6.4%

 

9.1%

 

p=0.048

Def/Prob ST

 

1.3%

 

2.0%

 

p=0.42

VLST

 

0.4%

 

1.8%

 

p=0.012

 

*

 

Endpoint Key

TVF = target vessel failure (a composite of TVR,
myocardial infarction and cardiac death)

TLR = target lesion revascularization

CD = cardiac death

MI = myocardial infarction

Def/Prob ST
= definite and probable stent thrombosis as defined by the Academic Research
Consortium (ARC)

VLST = very late stent thrombosis

ENDEAVOR Pooled Safety

Dr. Kandzari also presented a five-year update to a pooled analysis of safety
data from the Endeavor clinical program at TCT 2011. The analysis, called
ENDEAVOR Pooled Safety, involved 2,132 patients who received an Endeavor DES as
participants in one of six studies, including ENDEAVOR IV.

ENDEAVOR Pooled Safety shows that at five years of
follow-up, treatment with the Endeavor DES resulted in a significant reduction
in TLR and CD/MI, and was associated with no increased risk of stent thrombosis
in comparison to a bare-metal stent (BMS) control group including 596 patients
from ENDEAVOR II.

5-YEAR RESULTS

ENDEAVOR Pooled Safety

Endeavor DES vs. Driver BMS

Endpoint*

 

Endeavor

n=1,879

 

Driver

n=538

 

p Value

TLR

 

7.4%

 

16.5%

 

p<0.001

CD/MI

 

5.7%

 

8.4%

 

p=0.016

Def/Prob ST

 

0.9%

 

1.7%

 

p=0.10

VLST

 

0.3%

 

0.4%

 

p=0.85

NOTE: Data in this table are from post-hoc analysis; event
rates are unadjusted.

“These findings are even more relevant because most patients
in both groups were off dual-antiplatelet therapy by one year after stent
implantation,” explained Dr. Kandzari, whose paper titled “Dual antiplatelet
therapy duration and clinical outcomes following treatment with
zotarolimus-eluting stents” appeared in the October 2011 edition of JACC:
Cardiovascular Intervention. “The Endeavor DES exhibits a safety profile that
not only is durable through late-term follow-up but that also distinguishes it
from comparative devices.”

In collaboration with leading clinicians, researchers and
scientists worldwide, Medtronic offers the broadest range of innovative medical
technology for the interventional and surgical treatment of cardiovascular
disease and cardiac arrhythmias.

ABOUT MEDTRONIC

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical
technology – alleviating pain, restoring health and extending life for millions
of people around the world.

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech